RELMADA THERAPEUTICS, INC.

RLMD

Held by 2 specialist biotech funds

Share on X

Fund Holdings

OrbiMed Advisors Driehaus Capital

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Activist Filings

SC 13G/ARA Capital Management0.0%Feb 14, 2023

Position Details

OrbiMed AdvisorsNEWFeb 17, 2026

Shares: 2,610,600Value: $12.6M

# Signal Note: OrbiMed Initiates $12.6M Position in Relmada Therapeutics OrbiMed's new 2.6M share position in RLMD suggests conviction in the company's lead asset, esmethadone (d-methadone), a potential first-in-class NMDA receptor modulator for treatment-resistant depression. The timing likely reflects positioning ahead of near-term catalysts, potentially including Phase 3 efficacy/safety readouts or regulatory feedback on the NDA pathway. This represents meaningful validation from a top-tier healthcare allocator, though investors should monitor clinical trial execution and competitive landscape shifts in the burgeoning TRD market.

Driehaus CapitalNEW

More RLMD Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

RNA2 funds ANRO2 funds ARGX2 funds PRAX2 funds ALNY2 funds AXSM2 funds ASND2 funds EWTX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: Driehaus Capital Initiates RLMD Position Driehaus's $9.1M entry into Relmada suggests confidence in its late-stage pipeline, likely REL-1017 (esmethadone) for treatment-resistant depression (TRD), which showed positive Phase 3 data and carries potential for rapid regulatory approval given Fast Track designation. The timing aligns with anticipated catalysts including potential NDA submission in 2024 and label expansion discussions, offering growth-oriented capital a meaningful risk/reward before potential FDA decisions.